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OBJECTIVES This study examined plasma levels of certain matrix metalloproteinase (MMP) and tissue
inhibitor of matrix metalloproteinase (TIMP) species before and after alcohol-induced
myocardial infarction (MI) in patients with hypertrophic obstructive cardiomyopathy
(HOCM).
BACKGROUND Matrix metalloproteinases contribute to tissue remodeling, and endogenous control of MMP
activity is achieved by the concordant release and binding of TIMPs. Animal models of MI
have demonstrated a role for MMP activation in myocardial remodeling. However, the
temporal relationship of MMP and TIMP release following a controlled myocardial injury in
humans remains unknown.
METHODS Plasma levels for the gelatinases MMP-2 and MMP-9, and for the collagenases MMP-8 and
MMP-13, as well as TIMP-1 profiles were examined (by enzyme-linked immunosorbent
assay) at baseline and serially up to 60 h following alcohol injection into the septal perforator
artery in order to induce an MI in 51 patients with HOCM (age 55  2 years).
RESULTS Plasma creatine kinase (MB isoform), indicating myocardial injury, increased 2,150% 18 h
post-MI (p  0.05). Plasma MMP-9 increased by over 400% and MMP-8 by over 100%
from baseline values by 12 h post-MI (p  0.05 vs. baseline). A similar temporal profile was
not observed for MMP-2 and MMP-13. In addition, a concomitant increase in plasma
TIMP-1 levels did not occur post-MI. As a result, MMP/TIMP stoichiometry (MMP-9/
TIMP-1 ratio) increased significantly post-MI, suggestive of reduced TIMP-1 mediated
MMP-9 inhibition, which would potentially enhance extracellular myocardial remodeling.
CONCLUSIONS These unique results demonstrated that induction of a controlled myocardial injury in
humans, specifically through alcohol-induced MI, caused species- and time-dependent
perturbations of MMP/TIMP stoichiometry that would facilitate myocardial remodeling in
the early post-MI setting. (J Am Coll Cardiol 2002;40:2165–73) © 2002 by the American
College of Cardiology Foundation
An endogenous family of proteolytic enzymes responsible
for extracellular protein degradation and tissue remodeling
is the matrix metalloproteinases (MMPs). An important
control point for MMP activity is a second family of
proteins called the tissue inhibitors of matrix metallopro-
teinases (TIMPs) (1–5). Past clinical studies have demon-
strated that MMPs and TIMPs are expressed in normal
human left ventricular (LV) myocardium, and changes in
MMP expression and activity occur during LV remodeling
in patients with heart failure (6–9). Moreover, a cause-effect
relationship between the induction of MMPs and LV
myocardial remodeling has been established in animal
models (2,10 –13). For example, increased myocardial
MMP activation has been demonstrated to contribute to
LV dilation and remodeling in rodent models of myocardial
infarction (MI) (2,11). Past clinical studies have reported
changes in plasma MMPs in the post-MI period, which
suggests that increased synthesis and activation of MMPs
occur following myocardial injury and contribute to the
myocardial remodeling process (14–16). However, the di-
rect temporal relationship between MMP release and the
induction of a specific myocardial injury in patients remains
unknown.
Hypertrophic obstructive cardiomyopathy (HOCM) is a
genetic disorder most commonly characterized by exuberant
myocardial growth of the septal subaortic region of the left
ventricular outflow tract (LVOT) (17). Therefore, HOCM
can result in hemodynamically significant LVOT obstruc-
tion, eventual LV pump dysfunction, and consequent symp-
toms of LV failure. One current approach for the relief of
LVOT obstruction in patients with HOCM is selective
induction of an MI within the septal subaortic region
(17–20). Through a targeted injection of ethanol into the
septal perforator artery, selective destruction of myocardium
involved in the LVOT obstruction has been successfully
performed in a large number of patients (18–20). Concep-
tually, this treatment approach causes an alcohol-induced
MI and, therefore, provides a unique opportunity to address
several critical questions regarding the relationship between
MMPs and myocardial injury in patients. First, what is the
temporal profile of certain MMP species in the plasma of
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patients following an alcohol-induced MI? Second, is there
a relationship between the degree of myocardial injury
caused by an alcohol-induced MI and plasma MMP levels?
The goal of the present study was to address these specific
questions by serially measuring MMP and TIMP plasma
levels in patients with HOCM before and after alcohol-
induced MI.
METHODS
Patients. Patients (n  51) diagnosed with HOCM and
scheduled for elective alcohol septal ablation were entered
into the study after informed consent was obtained. This
protocol was reviewed and approved by the Institutional
Review Board of Baylor Medical College and the Medical
University of South Carolina. Average patient age was 55
2 years and the population consisted of 32 men and 19
women. At catheterization, the baseline LV to aortic
pressure gradient was 62  6 mm Hg, indicating a signif-
icant LVOT obstruction. The alcohol septal ablation pro-
cedure was performed as described previously (18,19).
Briefly, a balloon catheter was engaged into the septal
perforator artery and 2 to 5 ml of ethanol was injected. The
balloon was left inflated for 5 min following injection and
then removed. At six weeks post-alcohol injection, repeat
catheterization revealed a gradient of 25  4 mm Hg (p 
0.05), indicative of a reduction in the LVOT obstruction.
The changes in LV function and hemodynamics in patients
with HOCM following alcohol-induced MI have been well
described (17–20).
Plasma collection. Blood samples (5 cc) were collected
from a peripheral vein into chilled ethylenediamine-
tetraacetic acid tubes. The samples were centrifuged and the
decanted plasma aliquoted and stored at 70°C until assay.
Samples were collected at baseline (before catheterization
and septal ablation procedure) and at 4- to 6-h intervals for
up to 60 h post-alcohol injection.
MMP and TIMP assays. This study focused upon two
known classes of MMPs: the interstitial collagenases, which
include MMP-8 and MMP-13, and the gelatinases, which
include MMP-2 and MMP-9 (1–3). The best-
characterized TIMP is TIMP-1 (1,5). Accordingly, mea-
surements of TIMP-1 were also performed in the present
study. Quantification of MMP and TIMP species was
performed with enzyme-linked immunosorbent assay sys-
tems (Amersham Pharmacia Biotech, Buckinghamshire,
United Kingdom) using a two-site binding method as
described previously (7,21). For MMP-2 (RPN 2617), the
antisera used reacts against the proform of MMP-2
(proMMP-2) and does not react against the active form.
For MMP-9 (RPN 2614), the antiserum detects the pro-
form of the enzyme (proMMP-9). For MMP-8 (RPN
2619), the antiserum detects both proenzyme and active
forms of MMP-8. For MMP-13 (RPN 2621), the anti-
serum was developed to detect the proform of this enzyme.
For TIMP-1, the antiserum was developed in order to
detect the functional protein (RPN 2611). The coefficient of
variation for these assay systems was 3% to 5%; these
systems did not cross-react with other proteases, and the
sensitivity was at least 0.02 ng/ml.
Plasma samples were measured in parallel for total plasma
creatine kinase (CK) concentrations as well as the concen-
tration of the MB1 isoform using a microparticle enzyme
immunoassay procedure (AxSYM, Abbot Laboratories,
Chicago, Illinois).
Data analysis. The MMP, TIMP, and CK plasma levels
were first examined using an analysis of variance (ANOVA)
in which the treatment effect was time following alcohol
injection. Following this, the values were computed as a
percent change from baseline. These results were subjected
to ANOVA and then post-hoc mean separation using a
Bonferonni corrected t test for each time point in which the
null hypothesis was that the change from baseline was equal
to zero. To examine the relationship between the CK and
MMP values, the area under the concentration-time curve
for each patient was computed using a polygon integration
algorithm (SigmaPlot, Jandel, San Rafeal, California).
These points were then subjected to linear regression.
Values are expressed are expressed as mean  SEM. All
statistical procedures were performed utilizing SYSTAT
statistical software (SPSS Inc., Chicago, Illinois).
RESULTS
Alcohol injection into the septal perforator artery was
successfully performed in all 51 patients with HOCM, and
serial blood samples were collected. Baseline CK and MB1
fractions are presented in Table 1. Changes in plasma CK
and the MB1 isoform following alcohol injection are shown
in Figure 1. A significant rise in plasma total CK and MB1
isoform occurred by 6 h and peaked at approximately 24 h
following alcohol injection. Baseline MMP and TIMP-1
plasma levels are summarized in Table 1 and are within the
range of plasma levels previously reported for patients
(15,21). The changes in plasma MMP-2 and MMP-9
following alcohol injection are shown in Figure 2. A small
but statistically significant increase in plasma MMP-2
occurred at 4 h following alcohol injection. In contrast, a
robust increase in plasma MMP-9 occurred at 6 h following
alcohol injection and remained elevated for up to 50 h
post-injection. Plasma MMP-8 levels also increased by 6 h
Abbreviations and Acronyms
ANOVA  analysis of variance
CHF  congestive heart failure
CK  creatine kinase
HOCM  hypertrophic obstructive cardiomyopathy
LV  left ventricle/ventricular
LVOT  left ventricular outflow tract
MI  myocardial infarction
MMP  matrix metalloproteinases
TIMP  tissue inhibitor of matrix metalloproteinases
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post-injection and remained elevated for up to 60 h post-
injection (Fig. 3). Plasma MMP-13 levels did not signifi-
cantly increase at any time point after alcohol injection, but
actually decreased with a slight but significant change at
24 h following injection (Fig. 3). Plasma TIMP-1 levels
tended to increase at late time points following alcohol
injection, but this did not reach statistical significance (p 
0.15) (Fig. 4). However, the plasma MMP-9/TIMP-1 ratio
increased at 6 h following injection and remained increased
for up to 60 h post-alcohol injection (Fig. 4). A similar
change occurred for the MMP-8/TIMP-1 ratio, in which
this ratio significantly increased following alcohol injection
(data not shown). The area under the curve for the plasma
CK MB1 and the area under the time curve for MMP-9
were plotted for each patient and are shown in Figure 5. A
significant linear relationship was observed between CK
MB1 release and that of plasma MMP-9 levels.
DISCUSSION
The LV outflow obstruction caused by HOCM can be
relieved through the creation of a targeted myocardial lesion
(17–20). Specifically, the injection of ethyl alcohol into the
coronary artery supplying the hypertrophic region of the LV
causes sclerosis of the vessel and subsequent ischemia/
infarction of the targeted myocardium. However, little is
known about the cellular and extracellular events contribut-
ing to LV remodeling following alcohol-induced MI in
patients with HOCM. Changes in the levels of MMPs and
TIMPs have been reported in several cardiovascular disease
states, such as heart failure and aortic aneurysms (1–3).
Moreover, using animal models, a cause-effect relationship
has been established between MMP activation and the LV
remodeling process (10–13). Accordingly, the present study
serially measured changes in the plasma levels of selected
MMP and TIMP species in patients with HOCM follow-
ing alcohol-induced MI. The new and unique findings of
the present study were twofold. First, a robust release of
certain MMP species (MMP-8 and MMP-9) occurred
following intracoronary injection of alcohol in patients with
HOCM, which was not accompanied by a concomitant
increase in TIMP-1 levels. This resulted in an MMP-
TIMP stoichiometry that would favor myocardial matrix
degradation. Second, the release of certain MMPs was
sustained for up to 48 h following alcohol-induced MI and
was related to the degree of myocardial injury. These
findings provide a unique temporal profile of MMP and
TIMP release following a discrete myocardial injury in
humans.
This study is the first to profile plasma MMP and TIMP
species levels following alcohol-induced MI in patients.
However, past clinical reports have documented changes in
plasma MMP levels in patients with acute coronary syn-
dromes (14–16). For example, Kai et al. (16) reported that
plasma MMP-9 levels were elevated approximately 24 h
following an acute MI in patients. Inokubo et al. (15)
demonstrated that the elevation in plasma MMP-9 in
patients with acute coronary syndromes was due to a distinct
change in the great cardiac vein-aorta gradient, indicating
that the source for the elevated MMP-9 was the myocar-
dium. However, these past studies were not able to precisely
time the emergence of MMPs with respect to the onset of
myocardial injury. In addition, the location and magnitude
of the myocardial injury was not precisely defined in these
reports. The present study demonstrated that a discrete
myocardial injury induced in patients caused a time- and
species-dependent plasma release of MMPs. Although the
present study provides only temporal associative data re-
garding myocardial injury and remodeling, past animal
studies have clearly demonstrated a cause-effect relationship
between myocardial MMP induction and remodeling in the
setting of MI (2,11–13). Specifically, using transgenic mod-
els in which MMP gene expression has been modified
(12,13), or through the use of MMP pharmacologic inhi-
bition (11), it has been demonstrated that the expression,
synthesis, and release of MMP species play a fundamental
role in the initial wound healing response following MI, as
well as the myocardial remodeling that occurs from days to
weeks post-MI. Thus, in the present study, emergence of
MMPs into the plasma following alcohol-induced MI was
likely due to the local release of myocardial MMPs as part
of the initial wound healing process. However, it must be
recognized that plasma MMP and TIMP profiles were
measured following alcohol-induced sclerosis of a septal
perforating artery in patients with HOCM. Whether and to
what degree this pattern of MMP release occurs in patients
with an evolving MI secondary to coronary atherosclerosis/
thrombosis remains to be established.
At present, over 20 MMP species have been cloned and
cataloged (1–3,5,22). The major classes of MMPs include the
interstitial collagenases, such as MMP-1, MMP-13, and
MMP-8; the gelatinases, which include MMP-2 and
MMP-9; and the membrane-type MMPs. In the present
study, preliminary measurements failed to detect MMP-1
within the plasma of patients with HOCM. This finding may
have been the result of a relatively low abundance of this
particular MMP species in plasma and/or a relatively low
sensitivity of this enzyme-linked immunosorbent assay. In past
Table 1. Baseline Plasma CK Enzyme and MMP Levels in




CK (IU/l) 79.8  6.6
MB1 fraction (IU/l) 2.9  0.4
MMP-9 (ng/ml) 21.0  2.2
MMP-8 (ng/ml) 10.2  1.6
MMP-13 (ng/ml) 0.1  0.1
MMP-2 (ng/ml) 833.9  69.8
TIMP-1 (ng/ml) 1464.7  86.8
MMP-9/TIMP-1 0.019  0.003
CK  creatine kinase; MMP  matrix metalloproteinase; TIMP  tissue inhibitors
of matrix metalloproteinase.
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reports, myocardial MMP-1 levels were reduced by more than
50% in patients with congestive heart failure (CHF), suggest-
ing that this MMP species may not significantly contribute to
the myocardial remodeling process (6,7). Therefore, profiling
this particular MMP species was not pursued in the present
study. The MT-MMPs are transmembrane proteinases and,
therefore, whether this class of MMPs can be detected in
plasma is uncertain. Accordingly, the present study focused
upon soluble MMPs such as the gelatinases (MMP-2 and
MMP-9) and the collagenases (MMP-8, MMP-13) which
have been detected in plasma previously (14–16,21). In the
early period following alcohol-induced MI, a small increase in
MMP-2 plasma levels occurred, but rapidly returned to base-
line. This small rise was likely due to the release of intracellular
stores of MMP-2 from the area of myocardial injury. Past
studies that have measured LV myocardial abundance of
MMP-2 in the context of end-stage CHF have been equivocal
and appear to depend on the underlying etiology (6–9). An
important regulatory point with respect to MMP expression is
the induction of transcription factors that bind to promoter
Figure 1. (Top) The percent change in plasma total creatine kinase (CK) concentrations following alcohol injection into the septal perforator artery in
patients with hypertrophic obstructive cardiomyopathy. Peak plasma CK levels occurred at 10 to 20 h post-injection. (Bottom) The percent change in CK
MB1 isoform plasma concentrations following alcohol injection. A significant increase in CK-MB1 plasma levels was detected at 4 h and increased until
24 h following alcohol injection. *p  0.05 vs. time 0; baseline values.
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regions in MMP genes (5,22). The MMP-2 promoter region
is relatively devoid of transcription factor binding sites and,
therefore, transcriptional regulation of MMP-2 may be mini-
mal. This implies that MMP-2 may be constitutively expressed
and not necessarily selectively upregulated with acute patho-
logic stimuli, such as alcohol-induced MI. In contrast to
MMP-2, a robust and persistent increase in plasma levels of
MMP-9 occurred following alcohol-induced MI. Past in vitro
studies have demonstrated that preformed MMP-9 exists
within human platelets and is released with aggregation (23).
Furthermore, MMP-9 is synthesized and released by inflam-
matory cells, such as neutrophils (2–4). Thus, the basis for the
acute rise in plasma MMP-9 following alcohol-induced MI
was likely the release of MMP-9 from infiltrating neutrophils
and platelet aggregation at the site of myocardial injury.
Because the immunoassay detected only the proform of
MMP-9, the persistently elevated plasma levels of this MMP
species suggests that de novo synthesis occurred. In contrast to
Figure 2. (Top) A small but significant change in matrix metalloproteinase (MMP)-2 plasma levels from baseline was observed at 4 h following alcohol
injection. (Bottom) A significant increase in plasma MMP-9 levels occurred following alcohol injection and appeared to plateau for up to 50 h following
injection. *p  0.05 vs. time 0; baseline values.
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MMP-2, the MMP-9 gene contains multiple transcription
factor binding sites and is induced in vitro by a number of
cytokines (5,22). It has been demonstrated that all cell types
can synthesize and release MMP-9 (1–5). For example, oxi-
dative stress has been demonstrated to induce MMP-9 in
cardiac fibroblasts (24). In isolated LV myocyte preparations,
stimulation with bioactive molecules, such as tumor necrosis
factor-alpha, has been shown to induce MMP-9 release (25).
MMP-9 proteolytic substrates include the basement mem-
brane components as well as the activation of other MMP
species (1,3,4). In transgenic mice, MMP-9 gene deletion has
been clearly demonstrated to modify the myocardial remodel-
ing process post-MI (13). Therefore, increased levels of
MMP-9 may alter the myocyte interface to the extracellular
matrix and thereby facilitate LV remodeling.
The plasma levels of the interstitial collagenase MMP-8
increased markedly following alcohol-induced MI; MMP-8
has been primarily identified within neutrophils (1–5).
However, recent data suggest that MMP-8 may be ex-
pressed in a number of myocardial cell types (26). Thus, the
increased plasma MMP-8 levels following MI induction were
likely secondary to the acute inflammatory response as well as
Figure 3. (Top) Plasma matrix metalloproteinase (MMP)-8 levels increased in a time-dependent manner up to 24 h following alcohol injection of the septal
perforator artery in patients with hypertrophic obstructive cardiomyopathy and plateaued for longer periods following alcohol injection. (Bottom) A fall in
plasma MMP-13 levels was detected early following alcohol injection and was significant at 24 h. *p  0.05 vs. time 0; baseline values.
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release from the myocardium. Matrix metalloproteinase-13 has
been detected in human LV myocardium and is increased in
patients with end-stage CHF (7). The MMP-13 plasma
levels fell slightly following alcohol-induced MI and then
returned to baseline levels. The immunoassay for MMP-13
was directed against the proform of MMP-13. Thus, the
slight fall in circulating MMP-13 was likely due to en-
hanced activation and subsequent clearance. A number of
extracellular proteins have been demonstrated to be sub-
strates for MMP-8 and MMP-13, including the fibrillar
collagens. Thus, the activation of this class of MMPs
following alcohol-induced MI would significantly alter
myocardial extracellular structure and composition.
In the present study, TIMP-1 plasma levels did not
significantly change following alcohol-induced MI in pa-
tients with HOCM. Computing the relative stoichiometry
of MMPs to TIMPs can be used to define net MMP
proteolytic capacity (7,27). The stoichiometry for MMP-9/
TIMP-1 was computed following MI induction in patients
with HOCM. By 12 h post-MI, the plasma MMP-9/
TIMP-1 ratio was increased by over 500% from baseline.
These alterations in MMP-9/TIMP-1 stoichiometry may
favor prolonged MMP-9 activity within the myocardial
Figure 4. (Top) Plasma tissue inhibitor of matrix metalloproteinase (TIMP)-1 levels did not change immediately following alcohol injection, but tended
to rise at later time points; however, this did not reach statistical significance (p  0.15). (Bottom) The ratio of plasma matrix metalloproteinase
(MMP)-9/TIMP-1 levels was computed for each patient and plotted as a change from baseline values. A significant increase in this ratio occurred by 6 h
following alcohol injection. *p  0.15 vs. time 0; baseline values.
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tissue. Although TIMP-1 has been the best-characterized
TIMP, all four of the TIMP species have been identified
within the human myocardium (6,7,9). Whereas certain
TIMPs preferentially bind to certain proforms of MMPs,
all TIMPs bind in a 1:1 stoichiometric ratio to activated
MMPs. Therefore, whether and to what degree other
TIMP species are altered following alcohol-induced MI
remains to be established. Because TIMPs are an important
endogenous system for regulating local MMP activity,
profiling changes in the circulating levels of MMP/TIMP
ratios, and how these ratios may serve as a marker of MMP
activational states as well as an index of myocardial remod-
eling, warrant further study.
Study limitations and summary. Even though the present
study demonstrated an association between myocardial CK
and MMP release following alcohol-induced MI, the rela-
tionship between MMP release and the extent of myocar-
dial remodeling directly within the site of the septal lesion
was not examined. Past serial studies using magnetic reso-
nance imaging have demonstrated that remodeling of the
LVOT continues for several months following alcohol-
induced MI (28). Thus, future studies that serially measure
LV myocardial geometry and MMP/TIMP plasma levels
over an extended follow-up interval are warranted. Past
studies have demonstrated that the myocardium is an
important source for changes in plasma MMP levels
(15,21). Although this study clearly demonstrated that
release of certain MMP species into the plasma occurred
following alcohol-induced MI, whether and to what degree
this release was specific to the injured myocardium or was a
more global myocardial process remains to be defined. This
is the first study to quantify temporal changes in MMP and
TIMP levels following a discrete and defined myocardial
injury in humans. However, whether the results from this
study with respect to alcohol-induced MI can be extrapo-
lated to myocardial injury from coronary artery disease
remains to be established. These limitations notwithstand-
ing, the present study demonstrated a unique profile of
MMPs released into the plasma following alcohol-induced
MI in patients that was directly related to the degree of
myocardial injury. Animal models have clearly demon-
strated that MMPs play an important role in the acute
wound healing response following MI and that persistent
activation of this proteolytic system contributes to the
myocardial remodeling process (3,11–13). The results from
the present study suggest that monitoring MMP and TIMP
profiles may provide a novel approach in monitoring the
wound healing and myocardial remodeling process post-
MI.
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Figure 5. The area under the plasma concentration-time curve (AUC) was computed for each patient (n  51) with respect to plasma creatine kinase MB1
fraction and matrix metalloproteinase (MMP)-9 levels. A significant linear relationship was observed between these two parameters.
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